How Venetoclax Works: A BH3-Mimetic That Restores Apoptosis

The Apoptosis Checkpoint

The intrinsic (mitochondrial) apoptosis pathway is controlled by the BCL2 protein family. Pro-apoptotic effectors BAX and BAK, when activated, puncture the mitochondrial membrane and commit the cell to die. Anti-apoptotic proteins — BCL2, BCL-XL, MCL1 — hold this in check by binding and sequestering the pro-death 'BH3-only' activators such as BIM.

Many cancers survive by overexpressing an anti-apoptotic protein, effectively keeping a loaded system from firing.

What 'BH3-Mimetic' Means

Venetoclax is shaped to fit the same groove on BCL2 that a BH3-only protein binds — it mimics BH3. By occupying that groove it displaces sequestered BIM and other activators, which are then free to switch on BAX and BAK. Mitochondrial permeabilisation follows and the cell dies.

Venetoclax is selective for BCL2 and does not strongly inhibit BCL-XL, which is why it avoids the dose-limiting thrombocytopenia seen with earlier, less selective BH3-mimetics.

Why Some Cancers Are Exquisitely Sensitive

Chronic lymphocytic leukaemia cells are typically 'primed for death' and depend on BCL2 specifically to stay alive, so removing that dependence with venetoclax can cause rapid, deep responses. This can be dramatic enough to cause tumour lysis syndrome, and dosing is escalated slowly with prophylaxis and monitoring.

In acute myeloid leukaemia, venetoclax is combined with azacitidine or low-dose cytarabine because single-agent activity is limited.

Resistance

Because venetoclax only frees the death machinery, a cell can resist by leaning on a different anti-apoptotic protein — most often MCL1 or BCL-XL — so that displaced BIM is simply recaptured. Acquired BCL2 mutations that reduce drug binding (such as G101V), and changes in BAX or in upstream signalling, are also described.

This is the rationale for combinations and for MCL1-directed strategies in development.

Dosing, Ramp-Up and Tumour Lysis Prevention

Venetoclax is started at a low daily dose and increased in weekly steps over about five weeks to the target dose. This gradual ramp-up exists specifically to limit tumour lysis syndrome: each patient is assigned a risk category from tumour bulk and kidney function, and receives hydration, a uric-acid-lowering drug and blood-chemistry monitoring around each dose increase, sometimes as an inpatient.

It is an oral tablet taken with food. Strong CYP3A inhibitors, including some antifungals and antibiotics, markedly raise venetoclax levels and require dose reduction or avoidance. Neutropenia is the other common toxicity and is managed with growth-factor support and dose modification.

Testing and Context in CLL and AML

In chronic lymphocytic leukaemia, venetoclax-based regimens work regardless of TP53 mutation or 17p deletion status, which matters because those alterations predict poor response to chemoimmunotherapy; testing for them still guides overall strategy and prognosis. Fixed-duration venetoclax with an anti-CD20 antibody is a common approach, with minimal residual disease used to judge the depth of response.

In acute myeloid leukaemia, venetoclax with azacitidine has become a standard for patients unfit for intensive chemotherapy. Response is more likely with IDH1/2 or NPM1 mutations and less likely in some TP53, RAS and FLT3-ITD contexts, though the combination is not formally restricted by genotype.

Key Takeaways

• ·Venetoclax mimics a BH3-only protein and displaces BIM from BCL2, releasing BAX/BAK to trigger apoptosis.
• ·It is BCL2-selective, avoiding the platelet toxicity of dual BCL2/BCL-XL inhibition.
• ·Resistance often runs through MCL1 or BCL-XL dependence, or BCL2 binding-site mutations.